Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus

Acta Diabetologica

Volumn 52, Issue 4, 2015, Pages 649-662

  Rys, Przemyslaw ^a   Wojciechowski, Piotr ^a   Rogoz Sitek, Agnieszka ^a   Niesyczyński, Grzegorz ^a   Lis, Joanna ^b   Syta, Albert ^b   Malecki, Maciej T ^c,d  

^a HTA CONSULTING   (Poland)

^b Sanofi Aventis   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Insulin glargine; Insulin therapy; Long acting insulin analog; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PREMIXED INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MIDDLE AGED; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; STATISTICS AND NUMERICAL DATA;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84937817361     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0698-4     Document Type: Article

References (81)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
2. Handelsman Y, Mechanick JI, Blonde L et al (2011) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 17:1–53
3. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258
4. Control Group, Turnbull FM, Abraira C et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298. doi:10.1007/s00125-009-1470-0
5. Zoungas S, Patel A, Chalmers J et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418. doi:10.1056/NEJMoa1003795
6. Hsu P-F, Sung S-H, Cheng H-M et al (2013) Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care 36:894–900. doi:10.2337/dc12-0916
7. Gitt AK, Bramlage P, Binz C et al (2012) Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry. Eur J Prev Cardiol 19:765–772. doi:10.1177/1741826711411104
8. Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203. doi:10.2337/dc08-9025
9. National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians, London. http://www.nice.org.uk/guidance/cg66
10. Scottish Intercollegiate Guidelines Network (2010) Management of diabetes. A national clinical guideline. Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh, Scotland. http://www.sign.ac.uk/pdf/sign116.pdf
11. IDF, ISPAD (2011) Global IDF/ISPAD guideline for diabetes in childhood and adolescence
12. Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148
13. Gerich J, Becker RHA, Zhu R, Bolli GB (2006) Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 8:237–243. doi:10.1089/dia.2006.8.237
14. Rotenstein LS, Ran N, Shivers JP et al (2012) Opportunities and challenges for biosimilars: What’s on the horizon in the global insulin market? Clin Diabetes 30:138–150. doi:10.2337/diaclin.30.4.138
15. Pistrosch F, Köhler C, Schaper F et al (2013) Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol 50:587–595. doi:10.1007/s00592-012-0451-9
16. Esposito K, Chiodini P, Capuano A et al (2012) Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 35:2698–2705. doi:10.2337/dc12-0698
17. Fakhoury W, Lockhart I, Kotchie RW et al (2008) Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 82:156–163. doi:10.1159/000149569
18. Mullins P, Sharplin P, Yki-Jarvinen H et al (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 29:1607–1619. doi:10.1016/j.clinthera.2007.08.020
19. Rosenstock J, Dailey G, Massi-Benedetti M et al (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28:950–955
20. Bazzano LA, Lee LJ, Shi L et al (2008) Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 25:924–932. doi:10.1111/j.1464-5491.2008.02517.x
21. Clissold R, Clissold S (2007) Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid 2:89–110
22. Dailey G, Admane K, Mercier F, Owens D (2010) Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12:1019–1027. doi:10.1089/dia.2010.0063
23. Fonseca V, Davidson J, Home P et al (2010) Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 26:1621–1628. doi:10.1185/03007995.2010.485087
24. Halimi S, Raskin P, Liebl A et al (2005) Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 27:S57–S74
25. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD005613. doi:10.1002/14651858.CD005613.pub3
26. Ilag LL, Kerr L, Malone JK, Tan MH (2007) Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 29:1254–1270
27. Jansen HJ, Vervoort G, van der Graaf M, Tack CJ (2010) Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Neth J Med 68:359–366
28. Levien TL, Baker DE, White JR Jr, Campbell RK (2002) Insulin glargine: a new basal insulin. Ann Pharmacother 36:1019–1027
29. Monami M, Marchionni N, Mannucci E (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81:184–189. doi:10.1016/j.diabres.2008.04.007
30. Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ (2011) Long-acting insulin analogs: a review of “Real-World” effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 7(1):61–74. doi:10.2174/157339911794273892
31. Pontiroli AE, Miele L, Morabito A (2012) Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 14:433–446
32. Rolla AR, Rakel RE (2005) Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 27:1113–1125. doi:10.1016/j.clinthera.2005.07.003
33. Qayyum R, Bolen S, Maruthur N et al (2008) Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 149:549–559
34. Gough SCL (2007) A review of human and analogue insulin trials. Diabetes Res Clin Pract 77:1–15. doi:10.1016/j.diabres.2006.10.015
35. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. doi:10.1371/journal.pmed.1000097
36. Davidson J, Lacaya L, Jiang H et al (2010) Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract 16:818–828. doi:10.4158/EP09285.OR
37. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
38. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://www.cochrane-handbook.org
39. Hsia SH (2011) Insulin glargine compared to NPH among insulin-naïve, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract 91:293–299. doi:10.1016/j.diabres.2010.11.028
40. Forst T, Larbig M, Hohberg C et al (2010) Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes. Diabetes Obes Metab 12:437–441. doi:10.1111/j.1463-1326.2010.01209.x
41. Eliaschewitz FG, Calvo C, Valbuena H et al (2006) Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37:495–501
42. Fritsche A, Schweitzer MA, Häring H-U (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138:952–959
43. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442–451. doi:10.1007/s00125-005-0132-0
44. Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086
45. Massi Benedetti M, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189–196. doi:10.1055/s-2003-39080
46. Koivisto V, Cleall S, Pontiroli AE, Giugliano D (2011) Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes Obes Metab 13:1149–1157
47. Rosenstock J, Schwartz SL, Clark CM Jr et al (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636
48. Esposito K, Ciotola M, Maiorino MI et al (2008) Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 149:531–539
49. Strojek K, Shi C, Carey MA, Jacober SJ (2010) Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 12:916–922
50. Roach P, Woodworth JR (2002) Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 41:1043–1057
51. Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 52:1778–1788. doi:10.1007/s00125-009-1415-7
52. Al-Shaikh AR (2006) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Pak J Med Sci 22:14–17
53. Janka HU, Plewe G, Riddle MC et al (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254–259
54. Schiel R, Muller UA (2007) Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study. Exp Clin Endocrinol Diabetes 115:627–633
55. Buse JB, Wolffenbuttel BH, Herman WH et al (2009) DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 32:1007–1013
56. Kann PH, Wascher T, Zackova V et al (2006) Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 114:527–532. doi:10.1055/s-2006-949655
57. Raskin P, Allen E, Hollander P et al (2005) Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28:260–265
58. Robbins DC, Beisswenger PJ, Ceriello A et al (2007) Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 29:2349–2364
59. Strojek K, Bebakar W, Khutsoane D et al (2009) Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 28:2887–2894
60. Bowering K, Reed VA, Felicio J et al (2012) A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet Med 29:e263–e272
61. Miser WF, Arakaki R, Jiang H et al (2010) Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 32:896–908
62. Fritsche A, Larbig M, Owens D, Haring HU (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 12:115–123
63. Jain SM, Mao X, Escalante-Pulido M et al (2010) Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 12:967–975
64. Rosenstock J, Ahmann AJ, Colon G et al (2008) Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31:20–25
65. Rosenstock J, Davies M, Home PD et al (2008) A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:408–416. doi:10.1007/s00125-007-0911-x
66. Swinnen SG, Dain M-P, Aronson R et al (2010) A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 33:1176–1178. doi:10.2337/dc09-2294
67. Hollander P, Cooper J, Bregnhøj J, Pedersen CB (2008) A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:1976–1987. doi:10.1016/j.clinthera.2008.11.001
68. Raskin P, Gylvin T, Weng W, Chaykin L (2009) Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 25:542–548. doi:10.1002/dmrr.989
69. Saisho Y, Kou K, Tanaka K et al (2013) Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetol 50:987–988. doi:10.1007/s00592-012-0441-y
70. Swinnen SG, Simon AC, Holleman F et al (2011) Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006383.pub2
71. Piatti PM, Marone E, Mantero M et al (2013) Effect of normalization of fasting glucose by intensified insulin therapy and influence of eNOS polymorphisms on the incidence of restenosis after peripheral angioplasty in patients with type 2 diabetes: a randomized, open-label clinical trial. Acta Diabetol 50:373–382. doi:10.1007/s00592-012-0426-x
72. American Diabetes Association (2013) Standards of medical care in diabetes-2014. Diabetes Care 37:S14–S80. doi:10.2337/dc14-S014
73. Authors/Task Force Members, Rydén L, Grant PJ et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087. doi:10.1093/eurheartj/eht108
74. International Diabetes Federation (2012) Clinical Guidelines Task Force. Global guideline for type 2 diabetes. http://www.idf.org/global-guideline-type-2-diabetes-2012
75. Nicolucci A (2010) Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 47:87–95. doi:10.1007/s00592-010-0187-3
76. Janghorbani M, Dehghani M, Salehi-Marzijarani M (2012) Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer 3:137–146. doi:10.1007/s12672-012-0112-z
77. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA (2012) Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab 38:485–505. doi:10.1016/j.diabet.2012.08.011
78. Chen Y, Chen Q, Wang Z, Zhou J (2013) Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS ONE 8:e81594. doi:10.1371/journal.pone.0081594
79. Karlstad O, Starup-Linde J, Vestergaard P et al (2013) Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Saf 8:333–348
80. Tseng C-H (2013) Diabetes, insulin use, smoking, and pancreatic cancer mortality in Taiwan. Acta Diabetol 50:879–886. doi:10.1007/s00592-013-0471-0
81. Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328. doi:10.1056/NEJMoa1203858